Investors sold shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on strength during trading on Tuesday. $60.62 million flowed into the stock on the tick-up and $103.11 million flowed out of the stock on the tick-down, for a money net flow of $42.49 million out of the stock. Of all stocks tracked, Alexion Pharmaceuticals had the 2nd highest net out-flow for the day. Alexion Pharmaceuticals traded up $0.11 for the day and closed at $133.61

Several research firms have weighed in on ALXN. Cowen and Company reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, April 17th. Leerink Swann reaffirmed a “buy” rating and issued a $200.00 price target on shares of Alexion Pharmaceuticals in a research note on Sunday, July 17th. Jefferies Group reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, May 29th. Piper Jaffray Cos. reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Sunday, June 26th. Finally, Credit Suisse Group AG upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a report on Saturday, July 9th. Seven investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $186.61.

The firm has a market cap of $29.96 billion and a P/E ratio of 335.70. The stock’s 50 day moving average is $124.20 and its 200-day moving average is $139.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.17 by $0.04. The company had revenue of $753 million for the quarter, compared to the consensus estimate of $743.18 million. Alexion Pharmaceuticals’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same period last year, the firm posted $1.44 EPS. On average, equities research analysts expect that Alexion Pharmaceuticals Inc. will post $4.71 EPS for the current year.

In other Alexion Pharmaceuticals news, EVP Martin Mackay sold 4,097 shares of the firm’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $139.20, for a total transaction of $570,302.40. Following the completion of the sale, the executive vice president now directly owns 42,706 shares in the company, valued at approximately $5,944,675.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP John B. Moriarty sold 918 shares of the firm’s stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $135.72, for a total transaction of $124,590.96. Following the sale, the executive vice president now owns 51,360 shares of the company’s stock, valued at $6,970,579.20. The disclosure for this sale can be found here.

A number of hedge funds have recently added to or reduced their stakes in ALXN. Bank of Montreal Can raised its stake in Alexion Pharmaceuticals by 46.5% in the fourth quarter. Bank of Montreal Can now owns 230,164 shares of the biopharmaceutical company’s stock worth $43,902,000 after buying an additional 73,039 shares in the last quarter. Jennison Associates LLC raised its stake in Alexion Pharmaceuticals by 7.0% in the fourth quarter. Jennison Associates LLC now owns 7,346,024 shares of the biopharmaceutical company’s stock worth $1,401,254,000 after buying an additional 481,031 shares in the last quarter. Advantus Capital Management Inc raised its stake in Alexion Pharmaceuticals by 2.7% in the fourth quarter. Advantus Capital Management Inc now owns 21,882 shares of the biopharmaceutical company’s stock worth $4,174,000 after buying an additional 583 shares in the last quarter. KBC Group raised its stake in Alexion Pharmaceuticals by 46.7% in the third quarter. KBC Group now owns 22,138 shares of the biopharmaceutical company’s stock worth $3,462,000 after buying an additional 7,045 shares in the last quarter. Finally, Suntrust Banks Inc. raised its stake in Alexion Pharmaceuticals by 131.3% in the fourth quarter. Suntrust Banks Inc. now owns 35,654 shares of the biopharmaceutical company’s stock worth $6,800,000 after buying an additional 20,240 shares in the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.